• The natural inhibitor of neutrophil elastase, SLPI, is severely reduced in severe congenital neutropenia patients.
Introduction
Secretory leukocyte protease inhibitor (SLPI), an 11.7-kDa cationic serine protease, is a nonglycosylated protein composed of 2 highly homologous domains of 53 and 54 amino acids and a large number of positively charged residues. [1] [2] [3] It is expressed by a variety of cells, including granulocytes, monocytes/macrophages, and epithelial cells. Jacobsen et al have reported that SLPI messenger RNA (mRNA) expression is highest in granulocyte progenitor cell myelocytes/ metamyelocytes. 4 SLPI is one of the natural regulators of neutrophil elastase (NE). 5, 6 Dose-dependent reciprocal feedback regulation of NE and SLPI is well documented. 1, 7, 8 Autosomal-dominant mutations in the elastase, neutrophil expressed (ELANE) encoding the NE protein have been reported in the majority of patients with severe congenital neutropenia (CN). 9 CN is a primary immunodeficiency syndrome characterized by the absence of mature granulocytes in the BM and peripheral blood owing to the inability of BM granulocytic progenitor cells to differentiate into mature granulocytes at the stage of promyelocytes/myelocytes. 10 Elevated apoptosis and cell-cycle arrest in the G 0 /G 1 phase have been described in promyelocytes of CN patients. [11] [12] [13] [14] It is unclear how mutations in ELANE contribute to the failures in granulocytic differentiation, cell-cycle arrest, and elevated apoptosis. We and others have suggested activation of the unfolded protein response (UPR) by misfolded mutated NE protein in myeloid progenitors as one possible mechanism. [15] [16] [17] However, it is unknown whether activation of the UPR is the only mechanism responsible for the differentiation block in CN myeloid progenitors.
Recently, we found that expression levels of NE in myeloid cells and plasma of CN patients were severely downregulated independently of ELANE mutational status. 18 We also found markedly reduced levels of the myeloid-specific transcription factors lymphoid enhancer-binding factor 1 (LEF-1) and CCAAT/enhancer binding protein a (C/EBPa) in myeloid progenitors of CN patients harboring either ELANE or HCLS1 associated protein X-1 (HAX1) mutations. 19 ELANE mRNA expression is regulated by the binding of both LEF-1 and C/EBPa at the ELANE gene promoter; because the expression of these transcription factors was reduced, ELANE mRNA could not be activated. 19, 20 It remains unclear how diminished NE levels contribute to the defective granulopoiesis in CN patients. NE is a member of the chymotrypsin superfamily of serine proteinases expressed by neutrophils, monocytes, and mast cells. 21 Intracellularly, NE degrades foreign particles in phagosomes. Upon O.K. and W.E. contributed equally to this study.
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The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. cell activation, NE is secreted and degrades extracellular matrix proteins and some chemokine and cytokine receptors, including granulocyte colony-stimulating factor receptor (G-CSFR), granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor, C-X-C chemokine receptor type 4, and stromal cell-derived factor 1. [22] [23] [24] [25] NE also upregulates expression of cytokines such as interleukin-6 (IL-6), inerleukin-8, transforming growth factor-b (TGF-b), and GM-CSF. [26] [27] [28] We hypothesized that mutated NE or reduced expression of wildtype NE and its antiprotease, SLPI, might dysregulate intracellular signaling systems, ultimately resulting in defective myeloid differentiation, cell-cycle arrest, and apoptosis of myeloid BM progenitors observed in CN patients. SLPI expression is modulated by diverse stimuli, including lipopolysaccharide, NE, phorbol myristate acetate, and both pro-and anti-inflammatory cytokines. 1, 7, 8, 29 In addition to its antiprotease activity, SLPI has been shown to exert anti-inflammatory functions through downregulation of tumor necrosis factor-a (TNF-a). 29 SLPI also exhibits antiapoptotic activity through binding to annexin II on the cell surface 30 and has been shown to protect granulocytes from apoptosis. 31 Intriguingly, SLPI is also known to modulate intracellular signal transduction pathways, such as nuclear factor kB (NF-kB) and extracellular signal-regulated kinase (ERK). [32] [33] [34] In this latter context, it has been shown that SLPI is involved in the activation (phosphorylation) of ERK1/2 protein, 33 which plays an important role in G-CSF-triggered myeloid differentiation. 35, 36 Conversely, SLPI inhibits NF-kB activation in monocytes. It does this through 2 mechanisms: (1) by inhibiting the degradation of the NF-kB-binding inhibitory protein IkBa, an action that depends on the antiprotease activity of SLPI, and (2) by directly binding to NF-kB consensus sites on DNA and preventing p65 binding. 32 These actions reflect the ability of SLPI to rapidly enter cells and localize to the cytoplasm and nucleus. SLPI also has an impact on cell proliferation and the cell cycle through upregulation of cyclin D1 mRNA expression and downregulation of antiproliferative factors such as insulin-like growth factor binding protein-3. 37 SLPI is also involved in the regulation of growth factors, augmenting hepatocyte growth factor production by lung fibroblasts. 38 We detected severely reduced levels of SLPI in myeloid cells and plasma of CN patients owing to mutated or defective ELANE expression and demonstrated that a lack of SLPI led to diminished myeloid differentiation in vitro. Thus, we identified and characterized a new and unexpected mechanism of the regulation of myeloid differentiation by the protease inhibitor SLPI.
Materials and methods

Patients and controls
Twelve patients with CN harboring either ELANE (n 5 8) or HAX1 (n 5 4) mutations, 3 with other idiopathic neutropenia (IN), and 3 healthy volunteers participated in this study. All patients with neutropenia were treated long-term (.1 year) with G-CSF in a dose between 2 and 7.5 mg/kg per day at the time of study. None of the patients have developed acute myeloid leukemia or myelodysplastic syndrome so far. Three healthy volunteers received G-CSF in a dose of 5 mg/kg per day for 2 days before BM was taken. BM samples were collected in association with the annual follow-up recommended by the Severe Chronic Neutropenia International Registry. Approval for this study was obtained from the Hannover Medical School's institutional review board, and informed consent was obtained in accordance with the Declaration of Helsinki.
Purification and separation of CD34
1 and CD33 We obtained whole-cell lysates either through lysis of a defined number of cells in lysis buffer or through direct disruption in Laemmli loading buffer followed by brief sonication. We separated proteins by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and probed the blots with primary antibody either for 1 hour at room temperature or overnight at 4°C followed by washing.
Analysis of the SLPI protein by ELISA
The concentrations of SLPI in plasma were assayed in triplicate in appropriately diluted samples with an SLPI-specific enzyme-linked immunoabsorbent assay (ELISA) kit (R&D Systems). The detection limit of the assay was 25 pg/mL (SLPI).
In vitro proliferation and granulocytic differentiation experiments
We cultured 1 3 10 5 transduced and sorted red fluorescent protein (RFP) 
Colony-forming unit (CFU) assay
Human CD34 1 cells were transduced with SLPI-specific or control GFPtagged shRNA lentiviral constructs; GFP 1 cells were sorted and plated in 1 mL methylcellulose medium (5 3 10 3 /dish; Methocult H4230; Stemcell Technologies) supplemented with 10 ng/mL of G-CSF, 10 ng/mL of GM-CSF, 10 ng/mL of IL-3, 10 ng/mL of SCF, and 1 U of erythropoietin (R&D Systems). After 10 days of culture, the numbers of CFU-G, CFU-GM, and burst-forming unit-erythroid (BFU-E) colonies were calculated.
Statistical analysis
Statistical analysis was performed with the SPSS Version 9.0 statistical package (SPSS) . To analyze differences in mean values between 2 groups, a 2-sided unpaired Student t test was used. For the analysis of .2 groups, analysis of variance followed by Student t test was applied.
Results
Reduced SLPI mRNA and protein levels in CN patients harboring ELANE mutations
We investigated whether ELANE mutations or diminished ELANE expression affect the intracellular signaling program that operates during myeloid differentiation of hematopoietic cells. A search for proteins that are regulated by NE and show diminished expression in CD33 1 myeloid cells of CN patients identified SLPI, which was severely decreased at mRNA and/or protein levels in BM CD33 Figure 1D ).
Feedback regulation of SLPI by NE
We next examined whether NE regulates SLPI in hematopoietic cells. Indeed, we found that treatment with purified human NE activated SLPI mRNA synthesis in BM CD33 1 myeloid cells ( Figure 2A ). Moreover, transduction of CD34 1 hematopoietic progenitor cells or the myeloid cell lines NB4 and HL60 with wildtype (WT) ELANE cDNA resulted in a substantial increase in SLPI mRNA and protein content ( Figure 2B -E). We also studied whether ELANE mutants described in CN patients could induce SLPI expression. We used 3 ELANE mutants: C71R and 174-181del, which are frequent mutations found only in CN patients, and S126L, which is common to both CN and cyclic neutropenia patients. We found that all studied ELANE mutants failed to induce SLPI mRNA and protein expression ( Figure 2B -E). These data clearly show that WT ELANE induces SLPI expression, whereas mutant ELANE variants do not. It is known that mutated ELANE induces UPR and endoplasmic reticulum (ER) stress in hematopoietic cells. To evaluate whether SLPI is a downstream target of UPR effectors, we treated NB4 cells with dichlorodiphenyltrichloroethane (DDT) to induce UPR and measured SLPI mRNA and protein levels. Indeed, we found markedly reduced SLPI mRNA and protein levels in cells treated with DDT, in comparison with control samples ( Figure 2F -G). We also found diminished mRNA expression of C/EBPa and slightly elevated levels of C/EBPb transcription factors ( Figure 2F ). Moreover, mRNA expression levels of caspase-9 and of the antiapoptotic factor MCL1 were also dramatically activated by treatment of cells with DDT (supplemental Figure 1A) . Interestingly, we previously demonstrated a similar expression pattern of C/EBPa, C/EBPb, caspase-9, and MCL1 in myeloid cells of CN patients harboring ELANE mutations. 13, 39 Therefore, we concluded that one of the mechanisms of the defective signal transduction programs downstream of mutated ELANE, including downregulation of SLPI, could be activation of UPR.
To analyze whether the diminished ELANE levels seen in CN patients 10 have any effect on SLPI expression, we created shRNA constructs that specifically target ELANE and transduced the myeloid cell lines NB4 and HL60 as well as CD34
1 primary hematopoietic cells with these constructs. Indeed, we found that inhibition of ELANE expression led to inhibition of SLPI mRNA and Figure 3A-D) .
Taken together, these results indicate that diminished ELANE/ NE levels as well as mutations in ELANE result in reduced levels of SLPI mRNA and protein.
SLPI expression was downregulated in both groups of CN patients harboring either ELANE or HAX1 mutations. Previously, we found that hematopoietic-specific interaction partner of HAX1, HCLS1 protein, was downregulated in myeloid cells of CN patients. 40 Therefore, we next analyzed whether diminished levels of HAX1 or HCLS1 led to inhibition of SLPI levels. Indeed, we found that SLPI mRNA expression was markedly reduced in NB4 cells transduced with HAX1 or HCLS1 shRNA constructs, in comparison with controlshRNA-transduced cells ( Figure 3E ).
We also demonstrated diminished levels of transcription factors LEF-1 and C/EBPa, which are direct target genes of LEF-1, in myeloid cells of CN patients. 19 To assess if SPLI mRNA expression could be regulated by LEF-1 transcription factor in myeloid cells, we transduced NB4 cells with LEF-1 shRNA or control shRNA and measured SLPI mRNA levels. Indeed, we found reduced SLPI mRNA expression in LEF-1-shRNA-transduced cells, as compared with control-shRNA-transduced samples ( Figure 3F ). In silico analysis of the SLPI promoter revealed 3 binding sites of C/EBPa, which is a target gene of LEF-1. A quantitative chromatin immunoprecipitation (ChIP) assay in NB4 cells confirmed binding of C/EBPa to the SLPI promoter ( Figure 3G ). Taken together, these findings suggest that SLPI mRNA expression in myeloid cells is regulated by LEF-1-triggered activation of C/EBPa transcription factor and subsequent binding of C/EBPa to the SLPI promoter.
Induction of cell-cycle arrest and apoptosis and abrogation of myeloid differentiation by downregulation of SLPI We further analyzed whether diminished levels of SLPI are associated with the "maturation arrest" of myeloid cells seen in CN patients. We inhibited SLPI in CD34
1 BM hematopoietic progenitor cells and in the NB4 cell line using lentivirus-mediated transduction of SLPI-specific shRNA and analyzed G-CSF-or ATRA-induced myeloid differentiation, respectively. We found that G-CSF-induced myeloid differentiation was significantly diminished in CD34 Figure 4F ). In addition, we detected a significant elevation in the number of annexin V-positive apoptotic cells in the SLPI-shRNA-transduced group compared with control-shRNAtransduced CD34 1 cells ( Figure 4G ). 
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Overexpression of ELANE did not affected myeloid differentiation of CD34
1 cells upon treatment with G-CSF (supplemental Figure 3A) . In the contrast, inhibition of ELANE by shRNA had negative effect on G-CSF-triggered myeloid differentiation (supplemental Figure 3B ). At the same time, transduction of CD34 1 cells with ELANE mutants led to reduced proliferation and elevated apoptosis (supplemental Figure 4A ).
Diminished SLPI expression leads to elevated NF-kB levels and to diminished phospho-ERK1/2-mediated LEF-1 phosphorylation
It has been demonstrated that SLPI regulates TNF-a and NF-kB signaling cascades. 29, 32 Therefore, we evaluated whether these pathways are disrupted by inhibition of SLPI in hematopoietic cells. We measured TNF-a levels in culture supernatants of CD34 1 cells transduced with SLPI or control shRNA after induction of granulopoiesis by treatment of cells with G-CSF for 14 days. We did not found any differences in TNF-a levels between control-and SLPIshRNA-transduced groups (data not shown). At the same time, we identified diminished IkBa and elevated NF-kB p65 protein levels in NB4 cells transduced with SLPI shRNA, in comparison with control-shRNA-transduced cells ( Figure 5A ).
We next evaluated whether there was any functional connection between diminished SLPI levels and the defective LEF-1 expression and abrogated G-CSFR-triggered myeloid differentiation that we observed in CD33
1 myeloid progenitor cells of CN patients.
G-CSFR activation initiates phosphorylation of a number of proteins, including STAT5 (signal transducer and activator of transcription 5) and ERK1/2. Recently, it was shown that phosphorylated ERK1/2 regulates LEF-1 in hematopoietic cells. 41 It is also known that SLPI is involved in the phosphorylation of ERK1/2. 33 Therefore, we examined ERK1/2 phosphorylation levels in CD34 1 cells transduced with SLPI or control shRNA and treated with G-CSF for 10 minutes. We also measured phospho-STAT5 levels as a classical downstream effector of the G-CSFR activation. As expected, stimulation of control-shRNAtransduced cells with G-CSF resulted in phosphorylation of ERK1/2 and STAT5 proteins. In contrast, G-CSF failed to phosphorylate ERK1/2 and STAT5 after transduction of cells with SLPI-specific shRNA ( Figure 5B ). Moreover, using MotifScan software, we identified tyrosine residue (Tyr114) in the LEF-1 protein, which could be phosphorylated and generated rabbit polyclonal antibody specifically recognized this phosphotyrosine on the LEF-1 protein.
We verified the specificity of this antibody by FACS analysis of NB4 cells treated or not with phosphatase inhibitor cocktail (supplemental Figure 5A ). We found that reduced phosphorylated ERK1/2 levels were accompanied by a reduction in G-CSF-induced phosphorylation of LEF1 protein on tyrosine 114 ( Figure 5B ) and diminished expression of the LEF-1 target genes, c-Myc, survivin, and cyclin D1 ( Figure 5C ). Using gene set enrichment analysis (GSEA), we identified pathways affected by inhibition of SLPI in CD34
1 primary hematopoietic cells treated with G-CSF. Intriguingly, GSEA analysis revealed that the highest number of pathways that were markedly dysregulated in SLPI-shRNA-transduced cells was related to the c-Myc-triggered signaling ( Figure 6B ) and cellcycle signaling ( Figure 6C) . Notably, c-Myc is a well-known LEF-1 target gene, and we confirmed downregulation of c-Myc mRNA expression in SLPI-shRNA-transduced cells compared with control-shRNA-transduced cells by qRT-PCR ( Figure 6D ). Interestingly, the same genes that were downregulated in SLPIshRNA-transduced CD34 1 primary hematopoietic cells show diminished expression in CD33 1 myeloid progenitor cells of CN patients compared with healthy individuals and patients with idiopathic neutropenia ( Figure 6E ): cell-cycle regulatory genes (c-Myc, CDC25A, and CDC6), cyclins (CcnA2, CcnB1, and CcnE2), and cyclin-dependent kinases (Cdk1, Cdk2, and Cdkn6). Using Ingenuity Pathway Analysis software, we found that "hematological system development and function" pathway as well For personal use only. on July 15, 2017. by guest www.bloodjournal.org From as "hematopoiesis" pathway including 249 and 188 molecules, respectively, were affected in SLPI-shRNA-transduced cells, in comparison with control-shRNA-transduced samples (supplemental Table 1 ). Moreover, among the top affected associated network functions were Molecular Transport, Nucleic Acid Metabolism, Cell Cycle, Cellular Development, Cellular Growth and Proliferation, and Amino Acid Metabolism (supplemental Table 2 ). Among the affected molecular and cellular functions pathways were Cellular Development; Molecular Transport; DNA Replication, Recombination, and Repair; Cell Death and Survival; and Cellular Movement (supplemental Table 3 ).
Discussion
We demonstrate that the levels of SLPI, a natural inhibitor of NE, are severely downregulated in myeloid cells and plasma of CN patients compared with patients with idiopathic neutropenia and healthy individuals ( Figure 7) . NE is known to stimulate SLPI mRNA synthesis, 1, 7, 8 and we had previously demonstrated that NE mRNA and protein expression are severely downregulated in CN patients. 18 Here, we found that transduction of myeloid cells with WT NE induced an increase in SLPI mRNA and protein levels, whereas the 3 mutant forms of NE investigated were not able to induce SLPI expression. Our in vitro studies also showed that inhibition of NE in myeloid cells resulted in diminished SLPI expression. The mechanism by which NE induces SLPI mRNA expression is unclear. NE could be involved in the degradation of protein suppressors of SLPI or histones on regulatory regions of the SLPI gene. In all likelihood, mutated NE would not be capable of degrading SLPI suppressors; however, it is able to activate the UPR and ER stress in myeloid cells. [15] [16] [17] Indeed, induction of UPR and ER stress by DDT led to diminished expression of SLPI and C/EBPa and to increased mRNA levels of C/EBPb, caspase-9, and MCL1. Interestingly, similar changes in the expression levels of the above-mentioned factors were detected previously in myeloid cells of CN patients. 13, 39 It would be interesting to evaluate which signaling components of the UPR are involved in the inhibition of SLPI and C/EBPa. Another possible mechanism of SLPI downregulation in CN patients is that the diminished NE protein levels are not sufficient for induction of SLPI. We previously demonstrated that myeloid progenitors of CN patients exhibit a severely dysregulated myeloid-specific signaltransduction program with diminished expression of myeloidspecific transcription factors LEF-1 and C/EBPa and elevated expression of C/EBPb. 19, 39 We demonstrated that downregulation of SLPI is connected to this transcriptional deregulation: C/EBPa binds to the SLPI promoter and inhibition of LEF-1 led to diminished SLPI expression, most probably due to reduced levels of C/EBPa, which is a target gene of LEF-1. Intriguingly, we found diminished SLPI and ELANE levels in CN patients carrying either ELANE or HAX1 mutations. The severely diminished ELANE, LEF-1, and C/EBPa levels in patients with HAX1 mutations 19 contribute to the reduced levels of SLPI (Figure 7) . Moreover, we found that G-CSF-induced phosphorylation of the HAX1 interaction partner HCLS1 is defective in myeloid cells of CN patients. Diminished HCLS1 expression and phosphorylation due to mutations in HAX1 leads to downregulation of ELANE and therefore to diminished SLPI levels. 40 We showed that downregulation of SLPI in hematopoietic progenitor cells and in a myeloid cell line resulted in markedly diminished granulocytic differentiation without any effects on monocytopoiesis and erythropoiesis. Thus, one possible mechanism for the selective maturation arrest of granulopoiesis in CN patients could be defective SLPI synthesis. SLPI mRNA expression is downregulated in both myeloid progenitors and mature granulocytes of CN patients. It has been previously reported that SLPI is maximally expressed in myelocytes/metamyelocytes and that SLPI protein is secreted by granulocytes. 4, 5, 42 We identified a marked reduction in SLPI expression levels in CD33 1 cells (corresponding to myeloblasts, promyelocytes, and myelocytes), which are defective in CN patients, compared with SLPI expression in these cells of healthy individuals. We and others have detected intracellular SLPI protein in myeloid progenitors. 4 In myeloid cells, intracellular SLPI likely plays a role in regulating the signal transduction program that directs myeloid differentiation. SLPI modulates intracellular signaling pathways, such as NF-kB, ERK, and TGF-b, 32, 33, 43 and prevents synthesis of TNF-a and matrix metalloproteinases. 29, 44, 45 In line with published data, we detected diminished expression of IkBa and elevation of NFkB p65 after inhibition of SLPI (Figure 7) . However, we did not detect any differences in TNF-a synthesis by hematopoietic cells deficient in SLPI. Most probably, SLPI-dependent regulation of TNF-a is cell-type dependent. SLPI also induces activating phosphorylation of ERK1/2 in human ovarian cancer cells. 33 Interestingly, we found that phosphorylation of ERK1/2, which is an important player in myeloid differentiation, 34, 35 was almost completely abolished upon G-CSF-induced myeloid differentiation of SLPI-shRNA-transduced CD34 1 cells. It was published that LEF-1 is a target of ERK1/2-mediated phosphorylation in hematopoiesis. 39 Consistent with defective phosphorylation of ERK1/2, we found that the levels of phosphorylated LEF-1 and expression of LEF-1 target genes was severely diminished in SLPI-shRNA-transduced cells compared with cells transduced with control shRNA. Therefore, we suggest that, in the absence of SLPI, G-CSF fails to phosphorylate ERK1/2, which in turn leads to the diminished phosphorylation and activation of LEF-1 protein (Figure 7 ). Recently, we described a novel G-CSFR-triggered intracellular mechanism of granulopoiesis, reporting that G-CSF activates the enzyme nicotinamide phosphoribosyltransferase (Nampt), which is important for NAD 1 generation and activation of sirtuins, NAD
1
-dependent protein deacetylases. 39 Microarray analyses in 6 CN patients showed that elevated Nampt levels are associated with severely diminished SLPI levels. The mechanism whether SLPI is directly or indirectly regulated by Nampt has to be investigated. It would be interesting to evaluate whether granulocytic differentiation is affected in SLPI 2/2 mice. These mice exhibited impaired wound healing 46 and a lower survival rate after lipopolysaccharide administration. 47 In SLPI-knockout mice, not only high NE activity but also large amounts of TGF-b and IL-6 as well as elevated DNA-binding activities of NF-kB and C/EBPb were observed. 46, 47 High levels of SLPI have been demonstrated in cancer cells, including ovarian cancer, gastric cancer, and oral squamous cell carcinoma, 46, 48 and SLPI is involved in the proliferation 48-50 and survival of tumor cells and neutrophils. 30, 31 Consistent with this, myeloid cells of SLPI-deficient CN patients exhibit cell-cycle arrest and elevated apoptosis. [11] [12] [13] [14] Some of the activities of SLPI are independent of its protease inhibitory activity. 37, 50 In line with these observations, our microarray analyses of the intracellular signaling pathways affected by inhibition of SLPI in G-CSFtreated CD34
1 hematopoietic cells revealed that SLPI has a strong effect on c-Myc-triggered cell proliferation and the cell-cycle regulatory network (Figure 7 ). Signaling systems that regulate the cell cycle are also significantly affected by downregulation of c-Myc, CDC25A, CDC6, cyclins (CcnA2, CcnB1, and CcnE2), and cyclin-dependent kinases (Cdk1, Cdk2, and Cdkn6). Intriguingly, genes that were downregulated by shRNA-mediated knockdown of SLPI in hematopoietic cells are similar to those that are decreased in myeloid progenitors of CN patients. Whether Figure 7 . Proposed model of the abrogated granulopoiesis in CN patients due to the diminished SLPI levels. In CN patients harboring ELANE or HAX1 mutations, expression of LEF-1 transcription factor is severely downregulated. This resulted in the diminished expression of LEF-1 target genes, including ELANE and C/EBPa. Both decreased ELANE levels and mutated ELANE failed to induce SLPI, which is normally activated by wild-type ELANE. Low SLPI expression causes abrogated G-CSFtriggered phosphorylation of ERK1/2, phosphorylation and activation of LEF-1 transcription factor, c-Myc-triggered proliferation, and activation of cell-cycle genes. Expression of the myeloid-specific target gene of LEF-1, C/EBPa, is diminished and C/EBPa failed to activate the SLPI promoter. NF-kB signaling is also dysregulated. These pathological intracellular events ultimately lead to the defective granulocytic differentiation of hematopoietic cells in CN patients.
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Restoration of defective SLPI expression by treatment with recombinant SLPI protein may be a therapeutic option for reversing the maturation arrest of granulopoiesis in CN patients. Fixed doses of recombinant SLPI protein have been already used in in vivo studies. Because of its cationic, arginine-rich structure, SLPI binds predominantly to negatively charged cell membranes and is readily internalized. Accordingly, it has been reported that SLPI binds to annexin II protein on the cell surface of monocytes and macrophages. 30 Taken together, by searching for mechanisms of defective granulopoiesis, we identified a previously unrecognized function of SLPI as an essential regulator of myeloid differentiation. SLPI is thus a new-candidate myelopoiesis regulatory factor playing an important role in controlling the proliferation, differentiation, and cell cycle of myeloid cells by regulating intracellular signaling. 
